Department of Otorhinolaryngology, Head and Neck Surgery, Lund University, Lund, Sweden.
Int J Audiol. 2010 Oct;49(10):765-71. doi: 10.3109/14992027.2010.485595.
The aim of this study was to investigate long-term development of hearing in subjects who had received platinum-based chemotherapy in childhood or adolescence. Another aim was to assess the self-reported hearing loss handicap and compare it to audiometric measurements. Medical records from individuals diagnosed with childhood cancer and treated with platinum-based chemotherapy between 1985 and 2000 at the University Hospital in Lund Sweden were reviewed retrospectively. Fifteen subjects, who fulfilled the eligibility criteria set for the study, underwent a thorough audiometric evaluation. The results show that the hearing loss, in subjects with ototoxicity had increased after the end of treatment, to include also the lower frequencies. The largest deterioration in hearing thresholds, up to 55 dB HL, was found at frequencies above 2 kHz. The findings also reveal that the subjects have a considerably greater hearing loss handicap and disability than would be expected from the results of the audiometric evaluations. The conclusion of this study is that children and adolescence treated with platinum-based chemotherapy should have regular audiometric follow-up examinations, also many years after the end of treatment. Furthermore, assessments of self-reported hearing disability should be made during and after chemotherapy.
本研究旨在调查曾在儿童或青少年时期接受铂类化疗的受试者的听力长期发展情况。另一个目的是评估自我报告的听力损失障碍,并将其与听力测量进行比较。回顾性分析了瑞典隆德大学医院 1985 年至 2000 年间诊断为儿童癌症并接受铂类化疗的个体的病历。15 名符合研究设定标准的受试者接受了全面的听力评估。结果表明,具有耳毒性的受试者的听力损失在治疗结束后增加,包括低频。在 2 kHz 以上的频率上,听力阈值的最大恶化高达 55 dB HL。研究结果还表明,与听力评估结果相比,受试者的听力损失障碍和残疾程度要大得多。本研究的结论是,接受铂类化疗的儿童和青少年应在治疗结束后定期进行听力随访检查,甚至在多年后也应如此。此外,在化疗期间和之后应进行自我报告的听力障碍评估。